Company
Aratana Therapeutics
NASDAQ:PETX
Aratana Therapeutics is a pioneer in pet therapeutics focused on licensing, developing and commercializing innovative therapeutics for dogs and cats. Aratana means “new beginning” and it defines our mission of developing safe and effective therapeutics for unmet or underserved medical conditions in pets. Our goal is to provide veterinarians and pet owners with new therapeutics that are driven by science and specifically made for pets. We believe pets are family and they deserve the best quality care.
4 stories
Aratana Therapeutics shares drop after Stifel lowers pet medicine company to Hold
Aratana boasts a trio of drugs – Entyce, Nocita, and Galliprant – that have all been approved by the FDA to treat pets.
Aratana Therapeutics hands in new FDA drug application for its pain blocker for cats
Aratana Therapeutics wants to widen use of its painkiller NOCITA to include cats
Aratana slumps on delay of launch of canine appetite stimulation drug
The company said ENTYCE is now slated for release in late 2017.